GRAIL, Inc. (NASDAQ:GRAL) Receives Average Recommendation of “Hold” from Analysts

Shares of GRAIL, Inc. (NASDAQ:GRAL) have been given a consensus rating of “Hold” by the ten ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $67.7778.

Several analysts have recently issued reports on GRAL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Wolfe Research assumed coverage on shares of GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research note on Wednesday. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Mizuho boosted their price objective on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research note on Wednesday.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL announced a collaboration with Priority Health to make its Galleri multi-cancer early detection blood test available to self-insured employer groups, which supports broader commercial adoption of its core product. Article Title
• Neutral Sentiment: Multiple law firms issued reminders about the August 4 lead-plaintiff deadline in the pending securities class action against GRAIL, keeping the lawsuit in focus for investors. Article Title
• Neutral Sentiment: Hagens Berman and other firms continued probing allegations that GRAIL misled investors about the design and efficacy of the NHS-Galleri trial, but these updates mostly reflect ongoing legal process rather than a new company-specific development. Article Title
• Negative Sentiment: The securities class action itself remains a drag on sentiment, with allegations of investor harm tied to disclosures around the NHS-Galleri trial and a broad class period running from May 13, 2025 to February 19, 2026. Article Title

Insider Activity

In other news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider directly owned 163,738 shares of the company’s stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.83% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. N.E.W. Advisory Services LLC purchased a new stake in shares of GRAIL during the fourth quarter worth $26,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of GRAIL in the fourth quarter worth about $28,000. Elyxium Wealth LLC acquired a new position in GRAIL during the fourth quarter worth about $31,000. Comerica Bank boosted its position in GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in GRAIL by 15,733.3% during the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after acquiring an additional 472 shares in the last quarter.

GRAIL Price Performance

Shares of NASDAQ:GRAL opened at $72.62 on Friday. The business’s 50 day moving average price is $65.64 and its 200-day moving average price is $69.35. GRAIL has a 1 year low of $29.95 and a 1 year high of $118.84. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -7.00 and a beta of 3.22.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. On average, sell-side analysts expect that GRAIL will post -10.91 earnings per share for the current year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.